Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

GLP-1 stories

Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00
Oct 30, 2026

Patients use AI-edited photos to access weight-loss drugs, pharmacies warn

Pharmacies are warning that patients are increasingly using AI-edited photographs to make themselves appear heavier in order to fraudulently access weight-loss treatments such as Mounjaro and Wegovy. The pharmacies are calling for tougher verification checks to prevent such deceptions.

Oct 30, 2026·1 source
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Aug 30, 2026

Medicare launches pilot GLP-1 discount program with eligibility restrictions

Medicare introduced a pilot program offering some seniors GLP-1 drugs for as low as $50 per month, but many patients with the most serious illnesses don't qualify for the discount under current program rules.

Aug 30, 2026·2 sources
00
Jul 6, 2026

Online GLP-1 Prescription Services Found to Lack Clinical Oversight in Secret Shopper Study

A secret shopper investigation of 49 websites prescribing GLP-1 weight loss drugs confirmed experts' concerns about inadequate clinical oversight and fast, easy prescriptions with minimal medical evaluation.

Jul 6, 2026·1 source
00
Apr 29, 2026

Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications

Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.

Apr 29, 2026·1 source
00

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00
Apr 17, 2026

Scientists Behind GLP-1 Obesity Drugs Propose Dropping GLP-1 as Target

Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.

Apr 17, 2026·2 sources
00
Apr 14, 2026

States Drop Medicaid Coverage for GLP-1 Weight-Loss Drugs as Demand Surges

Rising demand and high costs are driving US states to scale back Medicaid coverage for GLP-1 weight-loss drugs, highlighting growing tensions between access, affordability, and public healthcare budgets.

Apr 14, 2026·3 sources
00

Top claims

  • ▪In 2024, Blackstone Inc. reached an agreement to fund trials for Moderna Inc.’s influenza vaccine, which subsequently received U.S. regulatory approval in summer 2026
  • ▪Pfizer Inc. will maintain full ownership and operational control over the clinical development program for berobenatide under its funding deal with Blackstone Inc.
  • ▪Blackstone Inc. has expanded its involvement in co-funding clinical drug development trials in recent years

Subtopics

Weight loss medications & GLP-1 drugs7GLP-1 medications6Lifestyle, Wellness and Nutrition6Weight management6Obesity treatment4Drug Policy, Pricing & Approval3GLP-1 / Weight-Loss Medications3Weight loss drugs3Clinical trials2Drug Approval and Clinical Trials2Drug development2Eli Lilly2GLP-1 drugs2Healthcare Access and Insurance2Medicare2Metabolic health2Novo Nordisk2Zepbound2AI content detection1AI misuse1Cardiovascular health.1Clinical evaluation1Clinical Informatics1Clinical Trial Design & Evaluation1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories